$2mil in the first month of sales without even trying; new...

$2mil in the first month of sales without even trying; new cancer drugs on the way; and an entire range of generic pharmaceuticals to be launched in a few months .... if you are starting to go lukewarm on resources this is still a very cheap and potentially profitable direction to look.

This from their last sales report:

Sales launch
Genepharm sold just over $2 million of generic pharmaceuticals in the month of April. Sales were
limited to the company’s first three products. The products include leading cholesterol drug
Simvastatin, an antibiotic and an antidiabetic drug.
“The company is very pleased with this start as it meets best scenario expectations and indicates
the strength and readiness of Genepharm’s sales and marketing personnel and systems,” said Mr
Dennis Bastas, CEO and Managing Director of Genepharm Australasia.
Genepharm notes that this is the very first month of sales and includes a component of forward
sales and no conclusions or forecasts should be based on this figure.
New TGA approvals
Genepharm has received marketing approval from the Therapeutic Goods Administration (TGA) for
its third anti-cancer drug. The approved drug, Doxorubicin, is one of Australia’s leading drugs used
in the treatment of cancer.
The company has previously stated that it also expected a further round of TGA product approvals in
time for new pharmacy product launches in August 2006. Genepharm is currently experiencing
delays with the TGA approval process and believes that some of these product approvals may be
delayed until later in the year.
New over-the-counter Genepharm products
From early next financial year the company expects to launch a range of new Genepharm branded
over-the-counter (OTC) medicines across pharmacies in Australia. The range of analgesics and
antihistamines will target the Australian pain relief and allergy markets.
“Genepharm has established a new partnership with a leading global supplier of pharmacy products
to release a new low cost range of the most popular OTC medicines. This is consistent with
Genepharm’s strategy to ensure quality and low cost supply with an expanding Genepharm suite of
products that will build our value proposition to pharmacy,” said Mr Bastas.

but strongly recommend you DYOR